|
[9005146.] رقم البحث : 9005146 - |
|
ROLE OF HELICOBACTER PYLORI ERADICATION USING CLARITHROMYCIN-BASED TRIPLE THERAPY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME / دورالتخلص من بكتريا هيليكوباكتر بيلوري باستخدام العلاج الثلاثي القائم على كلاريثروميسين في المرضى الذين يعانون من متلازمة القولون العصبي |
| |
قطاع الدراسات الصيدلية / الصيدلة الأكلينيكية |
| تخصص البحث : الصيدلة الأكلينيكية |
| |
Bulletin of Pharmaceutical sciences / |
| |
سارة يوسف محمد ( Sarahyousef30@yahoo.com - ) |
| |
د/ هايدى كرم الله رمضان - مؤلف رئيسي |
| |
الصيدلة الإكلينيكية |
| |
Background: Association between Helicobacter pylori (H. pylori) and irritable bowel syndrome (IBS) remains controversial. We evaluated the changes in symptoms and quality of life (QOL) in IBS patients following H. pylori eradication using clarithromycin-based triple therapy. Methods: Patients with moderate or severe IBS and positive H. pylori stool antigen were included and received clarithromycin-based triple therapy, followed by testing for H. pylori eradication after one month. IBS symptoms and IBS-QOL questionnaire were evaluated at the baseline and after H. pylori eradication. Results: 108 patients had H. pylori eradication. Following eradication, 66 patients reported IBS symptoms improvement, while 42 did not. The improved patients were significantly younger; mean age was 38.1 ± 11.7 (p= 0.03). IBS-C type predominated (42.4%) and postprandial fullness and early satiety as dyspeptic symptoms were higher in the improved group. The non-improved group showed a decrease in IBS-QOL subscales, significantly observed in dysphoria, interference with activity, health worry, and social reaction domains. The total IBS-QOL score was significantly higher in the improved versus the non-improved group (p= 0.000). Conclusion: H. pylori eradication did not improve IBS symptoms or QOL in all patients with IBS. QOL improved in young patients with dyspeptic symptoms and the IBS-C subtype. |
| |
 Download Paper |
تسجيل دخول 
